Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal D Shore

Showing results (161-170 of 312) with videos related to

Pageof 32
Sort By:
European Urology Oncology|December 24, 2023
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO StudyRonald Tutrone, Fred Saad, Daniel J George, et al.
Eclinicalmedicine|August 21, 2025
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysisStephen J Freedland, Ugo De Giorgi, Antti Rannikko, et al.
Future Oncology (London, England)|February 8, 2023
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS studyNeal D Shore, Felipe Cruz, Luke Nordquist, et al.
Prostate Cancer and Prostatic Diseases|March 2, 2024
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancerNeal D Shore, Emmanuel S Antonarakis, Ashley E Ross, et al.
BMC Urology|September 8, 2018
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
BMC Urology|October 5, 2018
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
The Journal of Sexual Medicine|October 15, 2013
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral liftKevin T McVary, Steven N Gange, Neal D Shore, et al.
European Urology Oncology|June 16, 2019
Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic ReviewStephen B Williams, Mohamed D Ray-Zack, Hogan K Hudgins, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by ageNeal D Shore, Ugo De Giorgi, Matko Kalac, et al.
JAMA Oncology|June 16, 2022
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical TrialNeal D Shore, Joseph Renzulli, Neil E Fleshner, et al.
Pageof 32

Showing results (161-170 of 312) with videos related to

Sort By:
Pageof 32
European Urology Oncology|December 24, 2023
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO StudyRonald Tutrone, Fred Saad, Daniel J George, et al.
Eclinicalmedicine|August 21, 2025
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysisStephen J Freedland, Ugo De Giorgi, Antti Rannikko, et al.
Future Oncology (London, England)|February 8, 2023
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS studyNeal D Shore, Felipe Cruz, Luke Nordquist, et al.
Prostate Cancer and Prostatic Diseases|March 2, 2024
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancerNeal D Shore, Emmanuel S Antonarakis, Ashley E Ross, et al.
BMC Urology|September 8, 2018
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
BMC Urology|October 5, 2018
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
The Journal of Sexual Medicine|October 15, 2013
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral liftKevin T McVary, Steven N Gange, Neal D Shore, et al.
European Urology Oncology|June 16, 2019
Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic ReviewStephen B Williams, Mohamed D Ray-Zack, Hogan K Hudgins, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by ageNeal D Shore, Ugo De Giorgi, Matko Kalac, et al.
JAMA Oncology|June 16, 2022
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical TrialNeal D Shore, Joseph Renzulli, Neil E Fleshner, et al.
Pageof 32